Which NVAF patients are candidates for NOACs?

Slides:



Advertisements
Similar presentations
Educational Event 23rd & 24th January 2013
Advertisements

Concomitant Antiplatelet and OAC Tx: Real-World Practice In the US, ~800,000 AF patients are on concomitant OAC and antiplatelet tx 1 Patients on chronic.
New Oral Anticoagulants (NOACs) Dabigatran and Rivaroxaban for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation Dr Dipti.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines COMBINATION WARFARIN + ASA THERAPY WHEN: TO USE, TO CONSIDER,
CLINICAL CASES.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Cross-Canada Collaboration to Promote Evidence-Based Use of Anticoagulants CADTH SYMPOSIUM APRIL 14, 2015.
AF and NOACs An UPDATE JULY 2014
Jim Hoehns, Pharm.D.. Edoxaban Oral factor Xa inhibitor Bioavailability: 62% Tmax: 1-2 hrs Elimination: 50% renal Half-life: 9-11 hours.
ROCKET AF Renal Dysfunction Substudy Objective Evaluate the 2950 patients in the per-protocol cohort with a baseline CrCl of 30 to 49 mL/min who received.
  Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban Target
Atrial Fibrillation and Anticoagulation
Massachusetts Medical Society, Health Policy/Health Systems 1 Warfarin Survey November 2007.
Anticoagulants Reducing the risk Amanda Powell & Sue Wooller May 2014.
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.
Net clinical benefit of OAC
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.
Uttam M Chouhan Pharmacist Glan Clwyd Hospital, BCUHB September 2017
A Challenging Case of Anticoagulant-Related GI Bleeding
Which NVAF patients are candidates for TSOACs?
Anticoagulation in Atrial Fibrillation
Covering the Bases in Cardioversion
CHA2DS2-VASc Scoring System General AF Treatment Guidance.
Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal  Gregory.
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although.
Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.
Randomized Evaluation of Long-term anticoagulant therapY
Click here for title Click here for subtitle
2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Laurent Macle, MD, John Cairns, MD, Kori.
When Is Adding Aspirin to NOACs Worth the Risk?
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
Thrombosis, Cancer, and NOACs
The ABCs of AF.
Access to NOAC Therapy:
Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.
Emergency Management of NOAC Bleeding
A New Era for NOACs:.
POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF NOACS IN AF
Anticoagulation Highlights From the American Heart Association Meeting 2017.
Up to Date on Which NOAC for Which Patient
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
Oral Anticoagulants in AFa,b A Brief History.
Surveying the Safety of NOACs in the Real World
NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS
The Essentials for Secondary Stroke Prevention
Stroke and AF.
Assessing the Risk for Stroke in Patients With Atrial Fibrillation
NOACS: Emerging data in ACS/IHD
Efficacy and Safety of Edoxaban in Patients With AF and HF
Access to NOAC Therapy:
Adherence in SPAF: Measures to Improve Care
Reversal Strategies for VKA: Truths and Misconceptions
Oral Anticoagulation in AF
Relative Risk of Events by CHA2DS2-VASc Score
Dos and Don’ts for High-Risk Elderly Patients With AF
Atrial Fibrillation.
Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials
Antithrombotic Therapy for Atrial Fibrillation
Pradaxa Jeopardy Copyright 2001.
Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?
2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Jason G. Andrade, MD, Atul Verma, MD,
The ABCs of AF.
An Unmet Need.
Disease Burden of VTE Phases of VTE Treatment.
5 Good Minutes on Atrial Fibrillation-related Stroke
NOACs and Reversal Agents
Erratum Canadian Journal of Cardiology
Figure 1. Decision-making process of stroke prevention in patients with AF from Asia. The decision-making process includes stroke risk evaluation, OAC.
ADAS Anticoagulant Dosing and Advisory Service
What's New in NOACs in AF?.
Presentation transcript:

Which NVAF patients are candidates for NOACs? Good candidates Have NVAF and meet CHADS2 criteria for anticoagulation AND ≥1 of the following Poor INR control in spite of good compliance with warfarin Unusual difficulty with regular INR checks True warfarin allergy Understand disadvantages and are willing to trade them for convenience of no lab monitoring Less compelling candidates Have indications other than NVAF for anticoagulation or an unacceptable risk-benefit ratio for warfarin use Are stable on warfarin with TTR > 72% Have CrCl < 30 ml/min Have poor INR control due to poor compliance Age ≥ 75 yoa? History of cardiac disease? History of GI bleed? At this point, I recommend cherry picking vs blanket approach